As filed with the Securities and Exchange Commission on November , 2001
Registration No. 333-
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-----------------
FORM S-3
REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OF 1933
-----------------
OSI SYSTEMS, INC.
(Exact Name of Registrant as Specified in Its Charter)
-----------------
12525 Chadron Avenue
Hawthorne, California 90250
California (310) 978-0516 33-0238801
(State or Jurisdiction of (Address, Including Zip Code, and Telephone Number (IRS Employer
Incorporation or Organization) Including Area Code, of Registrant's Principal Executive Offices) Identification Number)
-----------------
Deepak Chopra
President and Chief Executive Officer
12525 Chadron Avenue
Hawthorne, California 90250
(310) 978-0516
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code,
of Agent for Service)
-----------------
Copies to:
Gerald M. Chizever, Esq.
Kresimir Peharda, Esq.
Richman, Mann, Chizever, Phillips & Duboff
9601 Wilshire Boulevard, Penthouse
Beverly Hills, California 90210
(310) 274-8300; Fax: (310) 274-2831)
-----------------
Approximate Date of Commencement of Proposed Sale to the Public:
As soon as practicable from time to time after the effective date of this
registration statement.
-----------------
If the only securities being registered on this form are being offered
pursuant to dividend or interest reinvestment plans, please check the following
box. [_]
If any of the securities being registered on this form are to be offered on
a delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, other than securities offered only in connection with dividend or
interest reinvestment plans, check the following box. [X]
If this form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, check the following box and
list the Securities Act registration statement number of earlier effective
registration statement for the same offering. [_]
If this form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [_]
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box. [_]
CALCULATION OF REGISTRATION FEE
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
Proposed Maximum Proposed Maximum
Title of Each Class of Amount to be Offering Price Aggregate Offering Amount of
Securities to be Registered Registered Per Share(1) Price(1) Registration Fee
- ----------------------------------------------------------------------------------------------
Common Stock, no par value. 1,781,793 $12.635 $22,512,955 $5,628
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
(1) Estimated solely for purpose of calculating the registration fee in
accordance with Rule 457(c) under the Securities Act of 1933. Based on the
average of the high and low prices per share of Common Stock of the
registrant as reported on the NASDAQ National Market on November 14, 2001.
-----------------
The registrant hereby amends this registration statement on such date or
dates as may be necessary to delay its effective date until the registrant
shall file a further amendment which specifically states that this registration
statement shall thereafter become effective in accordance with Section 8(a) of
the Securities Act of 1933 or until this registration statement shall become
effective on such date as the Commission acting pursuant to said Section 8(a),
may determine.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
Information contained herein is subject to completion or amendment. A
registration statement relating to these securities has been filed with the
Securities and Exchange Commission. These securities may not be sold nor may
offers to buy be accepted prior to the time the registration statement becomes
effective. This prospectus shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of these securities
in any state in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such state.
Subject to Completion Dated , 2001
PROSPECTUS
1,781,793 SHARES
OSI SYSTEMS, INC.
COMMON STOCK
Certain of our stockholders (the "Selling Stockholders") are offering to
sell up to 1,781,793 shares of our common stock (the "Stock"). We are not
offering or selling any of the Stock. The Selling Stockholders may sell the
Stock on the open market at market price in ordinary broker transactions or in
negotiated transactions, and they may pay broker commissions in connection with
such transactions. We will not receive any of the proceeds of sale of the Stock
nor pay any broker commissions in connection with such sales. Our common stock
is quoted on the NASDAQ National Market under the symbol OSIS. On November 14,
2001, the closing price of the our common stock was $13.33 per share.
-----------------
You should carefully consider each of the risk factors described under RISK
FACTORS beginning on page 3 of this prospectus.
-----------------
The Selling Stockholders and any broker-dealer executing selling orders on
behalf of or purchasing from the Selling Stockholders may be deemed to be an
"underwriter" within the meaning of the Securities Act. Commissions received by
any such broker-dealer may be deemed to be underwriting commissions or
discounts under the Securities Act of 1933.
-----------------
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if
this prospectus is truthful or complete. Any representation to the contrary is
a criminal offense.
-----------------
The date of this prospectus is November , 2001
TABLE OF CONTENTS
Page
----
SUMMARY................................ 1
RISK FACTORS........................... 3
FORWARD-LOOKING STATEMENTS............. 8
USE OF PROCEEDS........................ 8
SELLING STOCKHOLDERS................... 9
PLAN OF DISTRIBUTION................... 10
LEGAL MATTERS.......................... 11
INCORPORATION OF DOCUMENTS BY REFERENCE 11
INDEMNIFICATION........................ 12
PROSPECTUS SUMMARY
You should read this summary together with the other information contained
in other parts of this prospectus and the documents which are incorporated by
reference. Because it is a summary, it does not contain all of the information
that you should consider before investing in our common stock. The Company will
provide copies of documents incorporated by reference to you upon request and
without cost to you.
We are a vertically-integrated, worldwide provider of devices, subsystems
and end-products based on optoelectronic technology. We design and manufacture
optoelectronic devices and value-added subsystems for original equipment
manufacturers ("OEMs") for use in a broad range of applications, including
security, medical diagnostics, fiber optics, telecommunications, gaming, office
automation, aerospace and defense electronics, computer peripherals and
industrial automation. In addition, we utilize our optoelectronic technology
and design capabilities to manufacture security and inspection products that we
market worldwide to end users under the "Rapiscan," "Secure" and "Metor" brand
names. These products are used to inspect people, baggage, cargo and other
objects for weapons, explosives, drugs and other contraband. In the medical
field, we manufacture and sell bone densitometers, which are used to provide
bone loss measurements in the diagnosis of osteoporosis. We also manufacture
and sell saturation of arterial hemoglobin ("SpO\\2\\") monitors and sensors
under the trade names Digital Dolphin(TM) and Dolphin 2000(TM). Digital
Dolphin(TM) model 2100 SpO\\2\\ monitors have received 510[k] approval for sale
in the United States.
In fiscal 2001, revenues from the sale of optoelectronic devices and
subsystems and medical imaging systems amounted to $59.3 million, or
approximately 53.4% of our revenues, while revenues from sales of security and
inspection products amounted to $51.8 million, or approximately 46.6% of our
revenues.
Unless the context otherwise requires, the terms "we" or "us" as used herein
includes OSI Systems, Inc., a California corporation, and its subsidiaries.
Business Overview
Our optoelectronic devices and subsystems are designed and manufactured
primarily for sale to OEMs, while our security products and medical imaging and
some monitoring systems are sold to end-users.
Optoelectronic Devices and Subsystems. Optoelectronic devices consist of
both active components, such as silicon photodiodes that sense light of varying
wavelengths and convert the light detected into electronic signals, and passive
components, such as lenses, prisms, filters and mirrors. An optoelectronic
subsystem typically consists of one or more optoelectronic devices that are
combined with other electronic components for integration into an end-product.
Optoelectronic devices and subsystems, and medical imaging systems, are used
for a wide variety of applications ranging from simple functions, such as the
detection of paper in the print path of a laser printer, to complex monitoring,
measurement or positioning functions, such as in industrial robotics where the
subsystem is used to detect the exact position, motion or size of another
object. Because optoelectronic devices and subsystems can be used in a wide
variety of measurement, control and monitoring applications, optoelectronics
may be used in a broad array of industrial applications. Optoelectronic devices
also are key components in the telecommunications and fiber optics market.
Medical Diagnostic and Imaging Systems. We have expanded into medical
diagnostic and imaging systems. We manufacture and distribute the DTX 200
(DEXACARE), a U.S. Food & Drug Administration ("FDA") approved forearm DEXA
(Dual Energy X-Ray) densitometer, which is used to diagnose osteoporosis as
well as to provide follow-up bone density measurements. We also produce the
ultrasound DTU-One, the first commercially available ultrasound scanner using
imaging capability for the diagnosis of osteoporosis. In September 2000, we
received pre-market approval ("PMA") from the FDA to sell the DTU-One in the
United States.
1
Security and Inspection Products. We manufacture and sell a range of
security and inspection equipment that we market under the "Rapiscan," "Secure"
and "Metor" brand names. To date, the security and inspection equipment has
principally been used at airports to inspect carry-on and checked baggage for
guns and knives. However, inspection products are increasingly being used for
both security purposes at a wide range of facilities other than airports and
for other non-security purposes. Our inspection and detection products combine
the use of x-ray technology with our core optoelectronic capabilities. Our
products combine dual or multi-energy x-ray technology with computer-enhanced
imaging technology to facilitate the detection of materials such as explosives,
narcotics, currency or other contraband. These systems range in size from
compact tabletop systems to large cargo pallet inspection systems weighing over
100,000 lbs.
Growth Strategy
Our objectives are to become a leading provider of specialized
optoelectronic products, to enhance our position in the international
inspection and detection marketplace and to leverage our expertise in the
optoelectronic technology industry by entering into new end-product markets on
a selective basis. The key elements of our strategy include:
. Leveraging our optoelectronic design and manufacturing expertise to
address new applications
. Further penetrating existing security and inspection markets and expanding
into other markets
. Capitalizing on vertical integration
. Capitalizing on global presence, and
. Selectively entering new end markets
Our business and operations are subject to numerous risks, some of which are
described in the RISK FACTORS section beginning on page 3 of this prospectus.
The Offering
This prospectus concerns an offering of up to 1,781,793 shares of our common
stock (the "Stock") by some of our current stockholders (the "Selling
Stockholders"). We are not offering or selling any of the Stock. We have
registered this offering in compliance with registration rights which we
granted to the Selling Stockholders when we sold the Stock to them. The Selling
Stockholders are not required to sell the Stock; sales of the Stock are
entirely at the discretion of each Selling Stockholder. The Selling
Stockholders may sell the Stock either on the open market at market price in
ordinary broker transactions or in negotiated transactions, and they may pay
broker commissions in connection with such transactions. We will not receive
any of the proceeds of sale of the Stock nor pay any broker commissions in
connection with such sales. Our common stock is quoted on the NASDAQ National
Market under the symbol "OSIS." On November 14, 2001, the closing price for our
stock was $13.33 per share. We will pay the costs of registering the offer and
sale of the Stock with the Securities and Exchange Commission (the "SEC") and
any required state securities agencies.
Common Stock Offered by the Selling Stockholders.... 1,781,793 Shares
NASDAQ National Market Symbol................................... OSIS
Deepak Chopra
President and Chief Executive Officer
OSI Systems, Inc.
12525 Chadron Avenue
Hawthorne, California 90250
(310) 978-0516
2
RISK FACTORS
Investing in our common stock involves a significant degree of risk. You
should carefully consider the following risk factors and all the other
information contained in this prospectus or incorporated by reference before
investing in our common stock. If any of the following risks actually occurs,
our business, financial condition and results of operations could suffer, in
which case the trading price of our common stock may decline.
Risks Related To Our Business
Fluctuations in our quarterly operating results may cause our stock price to
decline.
Given the nature of the markets in which we participate, we cannot reliably
predict future revenue and profitability. Changes in competitive, market and
economic conditions may cause us to adjust our operations. A high proportion of
our costs are fixed, due in part to our significant sales, research and
development, and manufacturing costs. Thus, small declines in revenue could
disproportionately affect our operating results in a quarter. Factors that may
affect our quarterly operating results and the market price of our common stock
include:
. demand for and market acceptance of our products;
. competitive pressures resulting in lower selling prices;
. adverse changes in the level of economic activity in regions in which we
do business;
. adverse changes in industries, such as semiconductors and electronics, on
which we are particularly dependent;
. changes in the portions of our revenue represented by our various products
and customers;
. delays or problems in the introduction of new products;
. our competitors' announcement or introduction of new products, services or
technological innovations;
. variations in our product mix;
. the timing and amount of our expenditures in anticipation of future sales;
. increased costs of raw materials or supplies; and
. changes in the volume or timing of product orders.
We face aggressive competition in many areas of our business. If we do not
compete effectively, our business will be harmed.
We encounter aggressive competition from numerous competitors in many areas
of our business. In the optoelectronic device and subsystem market and in the
medical diagnostic and imaging systems market, competition is based primarily
on factors such as expertise in the design and development of optoelectronic
devices, product quality, timeliness of delivery, price, customer technical
support, and on the ability to provide fully-integrated services from
application development and design through volume subsystem production. In the
security and inspection market, competition is based primarily on such factors
as product performance, functionality and quality, the over-all cost of the
system, prior customer relationships, technological capabilities of the
product, price, certification by government authorities, local market presence,
and breadth of sales and service organization. We may not be able to compete
effectively with all of these competitors. To remain competitive, we must
develop new products and periodically enhance our existing products in a timely
manner. We anticipate that we may have to adjust prices of many of our products
to stay competitive. In addition, new competitors may emerge, and entire
product lines may be threatened by new technologies or market trends that
reduce the value of these product lines.
3
The September 11 terrorist attacks have increased financial expectations that
may not materialize.
The September 11 terrorist attacks have created increased interest in our
security and detection products; however, we are uncertain whether the level of
demand will continue to be as high as anticipated. Additionally, it is
uncertain what, if any solutions, will be adopted as a result of the terrorism
and whether our products will be a part of the ultimate solution. Additionally,
should our products be considered as a part of the security solution, it is
unclear what the level may be and how quickly funding to purchase our products
may be made available. These factors may adversely impact us and create
unpredictability in revenues and operating results.
Our revenues are dependent on orders in the security and inspection products
category which has lengthy and unpredictable sales cycles.
Sales of security and inspection products depend in significant part upon
the decision of governmental agencies to upgrade or expand existing airports,
border crossing inspection sites and other security installations. Accordingly,
a portion of our sales of security inspection and detection products is often
subject to delays associated with the lengthy approval processes that often
accompany such capital expenditures. During these approval periods, we expend
significant financial and management resources in anticipation of future orders
that may not occur. If we fail to receive an order after expending such
resources, it could have a material adverse effect on our business, financial
condition and results of operations.
If we do not introduce new products in a timely manner, our products could
become obsolete, and our operating results would suffer.
We sell many of our products in industries characterized by rapid
technological changes, frequent new product and service introductions and
evolving industry standards. Without the timely introduction of new products
and enhancements, our products could become technologically obsolete over time,
in which case our revenue and operating results would suffer. The success of
our new product offerings will depend upon several factors, including our
ability to:
. accurately anticipate customer needs;
. innovate and develop new technologies and applications;
. successfully commercialize new technologies in a timely manner;
. price our products competitively and manufacture and deliver our products
in sufficient volumes and on time; and
. differentiate our offerings from our competitors' offerings.
Some of our products are used by our customers to develop, test and
manufacture their products. We therefore must anticipate industry trends and
develop products in advance of the commercialization of our customers'
products. In developing any new product, we may be required to make a
substantial investment before we can determine the commercial viability of the
new product. If we fail to accurately foresee our customers' needs and future
activities, we may invest heavily in research and development of products that
do not lead to significant revenue.
Interruptions to our ability to purchase raw materials and components may
adversely affect our profitability.
We purchase certain raw materials and subcomponents from third parties
pursuant to purchase orders placed from time to time. Purchase order terms
range from three months to one year at fixed costs, but we do not have
guaranteed long-term supply arrangements with our suppliers. Any material
interruption in our ability to purchase necessary raw materials or
subcomponents could have a material adverse effect on our business, financial
condition and results of operations.
4
We may not be able to successfully implement our acquisition strategy,
integrate acquired businesses into our existing business or make acquired
businesses profitable.
One of our strategies is to supplement our internal growth by acquiring
businesses and technologies that complement or augment our existing product
lines. This growth has placed, and may continue to place, significant demands
on our management, working capital and financial resources. We may be unable to
identify or complete promising acquisitions for many reasons, including:
. competition among buyers;
. the need for regulatory approvals, including antitrust approvals; and
. the high valuations of businesses.
Some of the businesses we may seek to acquire may be marginally profitable
or unprofitable. For these acquired businesses to achieve acceptable levels of
profitability, we must improve their management, operations, products and
market penetration. We may not be successful in this regard and may encounter
other difficulties in integrating acquired businesses into our existing
operations.
To finance our acquisitions, we may have to raise additional funds, through
either public or private financings. We may be unable to obtain such funds or
may be able to do so only on unfavorable terms.
Economic, political and other risks associated with international sales and
operations could adversely affect our sales.
In fiscal 1999, 2000, and 2001, revenues from shipments made outside of the
United States accounted for approximately 48.5%, 55.8% and 43.2%, respectively,
of our revenues. Of the revenues generated during fiscal 2001 from shipments
made to customers outside of the United States, 30.1% represented sales from
the United States to foreign customers, and the balance represented sales
generated by our foreign subsidiaries. Since we sell our products worldwide,
our businesses are subject to risks associated with doing business
internationally. We anticipate that revenue from international operations will
continue to represent a substantial portion of our total revenue. In addition,
many of our manufacturing facilities, employees and suppliers are located
outside the United States. Accordingly, our future results could be harmed by a
variety of factors, including:
. changes in foreign currency exchange rates;
. changes in a country's or region's political or economic conditions,
particularly in developing or emerging markets;
. longer payment cycles of foreign customers and difficulty of collecting
receivables in foreign jurisdictions;
. trade protection measures and import or export licensing requirements;
. differing tax laws and changes in those laws;
. difficulty in staffing and managing widespread operations;
. differing labor laws and changes in those laws;
. differing protection of intellectual property and changes in that
protection; and
. differing regulatory requirements and changes in those requirements.
Our failure to protect our intellectual property could impair our competitive
position.
We believe that our principal competitive strength is our ability to design,
develop and manufacture complex optoelectronic devices and subsystems for
various industry segments. While we own certain patents and
5
marks, other aspects of our business are not protected by patents or marks.
Accordingly, there are no legal barriers that prevent potential competitors
from copying certain of our products, processes and technologies or from
otherwise entering into operations in direct competition with us.
Our products may infringe on the intellectual property rights of others, and
resulting claims against us could be costly and prevent us from making or
selling certain products.
Third parties may seek to claim that our products and operations infringe
their patent or other intellectual property rights. We may incur significant
expense in any legal proceedings to protect our proprietary rights or to defend
infringement claims by third parties. In addition, claims of third parties
against us could result in awards of substantial damages or court orders that
could effectively prevent us from making, using or selling our products in the
U.S. or abroad.
A claim for damages could materially and adversely affect our financial
condition and results of operation.
Our business exposes us to potential product liability risks, particularly
with respect to our security and inspection products. There are many factors
beyond our control that could lead to liability claims, including the failure
of the products in which our subsystems are installed, the reliability of the
customer's operators of the inspection equipment, and the maintenance of the
inspection units by the customers. There can be no assurance that the amount of
product liability insurance that we carry will be sufficient to protect us from
product liability claims. A product liability claim in excess of the amount of
insurance we carry could have a material adverse effect on our business,
financial condition and results of operations.
Our ongoing success is dependent upon the continued availability of certain
key employees.
We are dependent in our operations on the continued availability of the
services of our employees, many of whom are individually key to our current and
future success, and the availability of new employees to implement our
company's growth plans. In particular, we are dependent upon the services of
Deepak Chopra, the Chairman of our Board of Directors, and our President and
Chief Executive Officer. We have entered into a 5-year employment agreement
with Mr. Chopra, which expires in April 2002 and maintain a $13.0 million
policy of key man life insurance on the life of Mr. Chopra. The market for
skilled employees is highly competitive, especially for employees in technical
fields. While our compensation programs are intended to attract and retain the
employees required for us to be successful, there can be no assurance that we
will be able to retain the services of all of our key employees or a sufficient
number to execute on our plans, nor can there be any assurances that we will be
able to continue to attract new employees as required.
Our failure to comply with environmental regulations may create significant
environmental liabilities and force us to modify our manufacturing process.
We are subject to various federal, state and local environmental laws,
ordinances and regulations relating to the use, storage, handling and disposal
of certain hazardous substances and wastes used or generated in the
manufacturing and assembly of our products. Under such laws, we may become
liable for the costs of removal or remediation of certain hazardous substances
or wastes that have been or are being disposed of offsite as wastes or that
have been or are being released on or in our facilities. Such laws may impose
liability without regard to whether we knew of, or caused, the release of such
hazardous substances or wastes. Any failure by us to comply with present or
future regulations could subject us to the imposition of substantial fines,
suspension of production, alteration of manufacturing processes or cessation of
operations, any of which could have a material adverse effect on our business,
financial condition and results of operations.
Changes in governmental regulations may reduce demand for our products or
increase our expenses.
We compete in markets in which we or our customers must comply with federal,
state, local and foreign regulations, such as environmental, health and safety
and food and drug regulations. We develop, configure and
6
market our products to meet customer needs created by these regulations. Any
significant change in these regulations could reduce demand for our products.
Risks Related To Our Capital Structure and Common Stock
Our officers and directors and stockholders affiliated with them own a large
percentage of our voting stock.
As of November 5, 2001, our directors and executive officers (including
Scope Industries, an affiliate of one of our directors), in the aggregate,
beneficially owned 32.2% of our outstanding common stock. Consequently, Scope
Industries, together with our directors and executive officers acting in
concert, will have the ability to significantly affect the election of our
directors and have a significant effect on the outcome of corporate actions
requiring shareholder approval. Such concentration may also have the effect of
delaying or preventing a change of control of our company.
Our articles of incorporation and other agreements contain provisions that
could discourage a takeover.
Our Articles of Incorporation authorize the Company's Board of Directors to
issue up to 10,000,000 shares of preferred stock in one or more series, to fix
the rights, preferences, privileges and restrictions granted to or imposed upon
any wholly unissued shares of preferred stock, to fix the number of shares
constituting any such series, and to fix the designation of any such series,
without further vote or action by its shareholders. The terms of any series of
preferred stock, which may include priority claims to assets and dividends and
special voting rights, could adversely affect the rights of the holders of
common stock and thereby reduce the value of our common stock. We have no
present plans to issue shares of preferred stock. The issuance of preferred
stock, coupled with the concentration of ownership in the directors and
executive officers, could discourage certain types of transactions involving an
actual or potential change in control of our company, including transactions in
which the holders of common stock might otherwise receive a premium for their
shares over then current prices, otherwise dilute the rights of holders of
common stock, and may limit the ability of such shareholders to cause or
approve transactions which they may deem to be in their best interests, all of
which could have a material adverse effect on the market price of our common
stock. We have in place a stockholder rights plan, adopted in 2000, under which
our stockholders are entitled to purchase shares of our preferred stock under
certain circumstances. These circumstances include the purchase of 20% or more
of the outstanding shares of common stock by a person or group, or the
announcement of a tender or exchange offer to acquire 20% or more of the
outstanding common stock. The stockholder rights plan may have the effect of
impeding or preventing certain types of transactions involving a change in
control of our company which could be beneficial to the stockholders.
Our articles of incorporation limit the liability of our directors which may
limit the remedies that we or our shareholders have available.
Our Articles of Incorporation provide that, pursuant to the California
Corporations Code, the liability of our directors for monetary damages shall be
eliminated to the fullest extent permissible under California law. This is
intended to eliminate the personal liability of a director for monetary damages
in an action brought by us, or in our right, for breach of a director's duties
to us or our shareholders and may limit the remedies available to us or our
shareholders. This provision does not eliminate the directors' fiduciary duty
and does not apply for certain liabilities: (i) for acts or omissions that
involve intentional misconduct or a knowing and culpable violation of law; (ii)
for acts or omissions that a director believes to be contrary to our best
interests or our shareholders or that involve the absence of good faith on the
part of the director; (iii) for any transaction from which a director derived
an improper personal benefit; (iv) for acts or omissions that show a reckless
disregard for the director's duty to us or our shareholders in circumstances in
which the director was aware, or should have been aware, in the ordinary course
of performing a director's duties, of a risk of serious injury to us or our
shareholders; (v) for acts or omissions that constitute an unexcused pattern of
inattention that amounts to an abdication of the director's duty to us or our
shareholders; (vi) with respect to certain transactions or the approval of
transactions in which a director has a material financial interest; and (vii)
expressly imposed by statute for approval of certain improper distributions to
shareholders or certain loans or guarantees.
7
FORWARD-LOOKING STATEMENTS
The statements contained in this prospectus that are not historical facts
are forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933. These forward-looking statements may be identified by
the use of forward-looking terms such as "believes," "expects," "may", "will,"
"should" or "anticipates" or by discussions of strategy that involve risks and
uncertainties. From time to time, we have made or may make forward-looking
statements, orally or in writing. These forward-looking statements include
statements regarding anticipated future revenues, sales, operations, demand,
competition, capital expenditures, credit arrangements, and other statements
regarding matters that are not historical facts, involve predictions which are
based upon a number of future conditions that ultimately may prove to be
inaccurate. Our actual results, performance or achievements could differ
materially from the results expressed in, or implied by, these forward-looking
statements. Factors that may cause or contribute to such differences include
those discussed under Risk Factors, above, in our Form 10-K for fiscal year
ended June 30, 2001, in Business and in Management's Discussion and Analysis of
Financial Condition and Results of Operations, as well as those discussed
elsewhere in this prospectus. These factors, of course, do not include all
factors which might affect our business and financial condition.
USE OF PROCEEDS
The Selling Stockholders selling the Stock and will receive all of the
proceeds from any sales. We will not receive any sales proceeds.
8
SELLING STOCKHOLDERS
All of the Stock being offered in this prospectus is being offered by the
Selling Stockholders listed below. We have registered this offering because of
registration rights we granted to the Selling Stockholders when we sold the
Stock to them. The Selling Stockholders are not required to sell all or any of
the Stock.
Shares Owned Shares to be
Before Sold in Shares Owned
Name Offering(1) Offering After Offering(2)
- ---- ------------ ------------ -----------------
TELUS Foreign Equity Active Pool(3).................................. 7,700 4,000 3,700*
Retail Employees Superannuation Pty Ltd(3)........................... 17,400 5,000 12,400*
WMP (Dublin) Global Smaller Companies Equity(3)...................... 6,800 2,000 4,800*
NZFunds Global Small Companies Trust(3).............................. 19,500 4,000 15,500*
JB Were Global Small Companies Fund(3)............................... 35,600 6,000 29,600*
Hartford Capital Appreciation Fund(3)................................ 800,000 800,000 --
WTC-CIF Specialty Growth Equity Portfolio(3)......................... 5,000 5,000 --
BCTEL Pension Plan for Management & Exempt Employees(3).............. 6,000 6,000 --
Pine Ridge Financial Inc.(4)......................................... 312,872 297,872 15,000*
Cranshire Capital, L.P............................................... 340,425 340,425 --
J. Steven Emerson IRA, Bear Stearns Securities Corp, Custodian....... 25,000 25,000 --
J. Steven Emerson IRA, II Bear Stearns Securities Corp, Custodian.... 40,000 40,000 --
Vertical Ventures LLC (5)............................................ 42,553 42,553 --
Vertical International Ltd.(6)....................................... 76,596 76,596 --
Westfield Life Sciences Fund L.P..................................... 27,200 27,200 --
Westfield Life Sciences Fund, L.P. II................................ 15,300 15,300 --
Roth Capital Partners, LLC(7)........................................ 84,847 84,847 --
Total............................................................. 1,862,793 1,781,793 81,000*
- --------
Percentage of ownership for each holder is calculated based on 8,535,109 shares
of common stock outstanding on November 5, 2001. Beneficial ownership is
determined in accordance with the SEC Rule 13d-3 and generally includes shares
over which the holder has voting or investment power, subject to community
property laws. All shares of common stock obtainable upon conversion of
securities or exercise of stock options or warrants (including those that are
not currently exercisable but will become exercisable within 60 days hereafter)
are considered to be beneficially owned by the person holding the options or
warrants for computing that person's percentage, but are not treated as
outstanding for computing the percentage of any other person.
(1) Includes shares of common stock covered by this prospectus.
(2) Assumes the completion of this offering and that the Selling Stockholders
dispose of all of their shares of common stock covered by this prospectus,
that they do not dispose of common stock owned but not covered by this
prospectus and that they do not acquire any additional shares of common
stock.
(3) Shared voting and dispositive ownership with Wellington Management Company,
LLP. Wellington may be deemed to have shared beneficial ownership of a
total of 832,000 shares of common stock. Wellington disclaims beneficial
ownership of such shares.
(4) By reason of an investment management agreement, Cavallo Capital Corp. has
investment and voting power over all shares held by Pine Ridge Financial,
Inc. Avi Vigder is the managing director of Cavallo Capital.
(5) Joshua Silverman, as managing member of Vertical Ventures LLC, has sole
investment and voting power over all the shares owned by Vertical Ventures
LLC.
(6) By reason of an investment management agreement, Joshua Silverman, a
principal of Vertical Ventures LLC, has sole investment and voting power
over all of the shares owned by Vertical International Ltd. To the extent
this results in Vertical Ventures LLC being deemed to be a beneficial owner
of shares owned by Vertical International Ltd., Vertical Ventures LLC
disclaims such beneficial ownership.
(7) Includes 84,847 shares of common stock underlying warrants which are not
exercisable until May 2002.
* Less than 1%.
9
PLAN OF DISTRIBUTION
The Selling Stockholders and any of their pledgees, assignees and
successors-in-interest may, from time to time, sell any or all of their shares
of common stock on any stock exchange, market or trading facility on which the
shares are traded or in private transactions. These sales may be at fixed or
negotiated prices. The Selling Stockholders may use any one or more of the
following methods when selling shares:
. ordinary brokerage transactions and transactions in which the
broker-dealer solicits purchasers;
. block trades in which the broker-dealer will attempt to sell the shares as
agent but may position and resell a portion of the block as principal to
facilitate the transaction;
. purchases by a broker-dealer as principal and resale by the broker-dealer
for its account;
. an exchange distribution in accordance with the rules of the applicable
exchange;
. privately negotiated transactions;
. short sales;
. broker-dealers may agree with the Selling Stockholders to sell a specified
number of such shares at a stipulated price per share;
. a combination of any such methods of sale; and
. any other method permitted pursuant to applicable law.
The Selling Stockholders may also sell shares under Rule 144 under the
Securities Act of 1933 (the "Securities Act"), if available, rather than under
this prospectus.
Broker-dealers engaged by the Selling Stockholders may arrange for other
brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the Selling Stockholders (or, if any broker-dealer acts as
agent for the purchaser of shares, from the purchaser) in amounts to be
negotiated. The Selling Stockholders do not expect these commissions and
discounts to exceed what is customary in the types of transactions involved.
The Selling Stockholders may from time to time pledge or grant a security
interest in some or all of the shares or common stock owned by them and, if
they default in the performance of their secured obligations, the pledgees or
secured parties may offer and sell the shares of common stock from time to time
under this prospectus, or under an amendment to this prospectus under Rule
424(b)(3) or other applicable provision of the Securities Act amending the list
of Selling Stockholders to include the pledgee, transferee or other successors
in interest as Selling Stockholders under this prospectus.
The Selling Stockholders also may transfer the shares of common stock in
other circumstances, in which case the transferees, pledgees or other
successors in interest will be the selling beneficial owners for purposes of
this prospectus.
The Selling Stockholders and any broker-dealers or agents that are involved
in selling shares of common stock may be deemed to be "underwriters'' within
the meaning of the Securities Act in connection with such sales. In such event,
any commissions received by such broker-dealers or agents and any profit on the
resale of shares purchased by them may be deemed to be underwriting commissions
or discounts under the Securities Act. The Selling Stockholders have informed
us that they do not have any agreement or understanding, directly or
indirectly, with any person to distribute the Stock.
We are required to pay all fees and expenses incident to the registration of
the Stock. We have agreed to indemnify the Selling Stockholders against certain
losses, claims, damages and liabilities, including liabilities under the
Securities Act.
10
LEGAL MATTERS
The law firm of Richman, Mann, Chizever, Phillips & Duboff, of Beverly
Hills, California, will pass upon the validity of the securities offered by
this prospectus.
INCORPORATION OF DOCUMENTS BY REFERENCE
The SEC allows us to "incorporate by reference" in this prospectus certain
information which we file with the SEC. This means we can fulfill, and
fulfilled, our obligations to provide you with certain important information by
referring you to other documents which we have filed with the SEC. The
information which is incorporated by reference is an important part of this
prospectus.
We are incorporating by reference in this prospectus the following documents
which we have filed, or may later file, with the SEC under the Securities
Exchange Act of 1934 (the "Exchange Act"). The information we file with the SEC
later will automatically update and supersede the present information.
1. Our Annual Report on Form 10-K for the fiscal year ended June 30, 2001
(SEC file number 0-23125).
2. Our Quarterly Report on Form 10-Q for the three months ended September
30, 2001 (SEC file number 0-23125).
3. All reports which we file with the SEC under the Exchange Act after the
date of the initial registration statement of which this prospectus is a
part and prior to the effective date of such registration statement.
4. The description of our common stock in our registration statement on
Form 8-A (File No. 0-24394) filed under the Exchange Act on September
24, 1997, which, in turn, incorporated such description by reference to
page 54 of the Company's Preliminary Prospectus, dated August 27, 1997,
filed with the Securities and Exchange Commission on September 2, 1997,
as part of the Company's Registration Statement on Form S-1 (No.
333-29179), and any amendments or reports filed to update the
description; and,
All documents which we file under Section 13(a), 13(c), 14 or 15(d) of the
Securities Exchange Act of 1934 between the date of this prospectus and the
termination of the offering shall be deemed to be incorporated by reference
into this prospectus.
We will provide to each person to whom a prospectus is delivered, including
any beneficial owner, a copy of any or all of the information which is
incorporated by reference in this prospectus but which is not delivered with
this prospectus. We will provide such information, at no cost to the requesting
person, upon written or oral request made to:
Deepak Chopra
President and Chief Executive Officer
12525 Chadron Avenue
Hawthorne, California 90250
(310) 978-0516
10.1
You should rely only on the information in this prospectus or any prospectus
supplement or incorporated by reference in them. We have not authorized anyone
else to provide you with different information. Offers of the securities are
being made only in states where the offers are permitted. You should not assume
that the information in this prospectus or any prospectus supplement is
accurate as of any date other than the date on the front of those documents. If
information in incorporated documents conflicts with information in this
prospectus, you should rely on the most recent information. If information in
an incorporated document conflicts with information in another incorporated
document, you should rely on the most recent incorporated document.
This prospectus is part of a Registration Statement on Form S-3 that has
been filed with the SEC. It does not include all of the information that is in
the registration statement and the additional documents filed as exhibits with
it. For more detailed information, you should read the exhibits themselves.
We are subject to the informational requirements of the Exchange Act and, in
accordance with it, are required to file reports, proxy and information
statements, and other information with the SEC. Such reports, proxy and
information statements and other information can be inspected and copied at the
SEC's Public Reference Room at 450 Fifth Street, N.W., Washington, D.C. 20549.
The public may obtain information about the operation of the Public Reference
Room by calling the SEC at 1-800-SEC-0330. We electronically file reports,
proxy and information statements, and other information with the SEC. The SEC
maintains an Internet website that contains our electronically filed reports,
proxy and information statements, and other information at http://www.sec.gov.
We maintain an Internet website at http://www.osi-systems.com. Our common stock
is traded on the NASDAQ National Market under the symbol OSIS, and our SEC
reports, proxy statements and other information concerning us also can be
inspected at the offices of Nasdaq Operations, 1735 K Street, N.W., Washington,
D.C. 20006.
11
INDEMNIFICATION
Our articles of incorporation allows us to indemnify our officers and
directors to the maximum extent allowed under California law. This includes
indemnification for liability which could arise under the Securities Act.
Insofar as indemnification for liabilities arising under the Securities Act of
1933 may be permitted to directors, officers or persons controlling the
registrant under these provisions, the registrant has been informed that in the
opinion of the Securities and Exchange Commission such indemnification is
against public policy as expressed in the Act and is therefore unenforceable.
12
- --------------------------------------
- --------------------------------------
-----------------
No dealer, salesperson or other person has been authorized to give any
information or to make any representations not contained in this prospectus in
connection with the offering covered by this prospectus. If given or made, such
information or representations must not be relied upon as having been
authorized by OSI Systems, Inc., a Selling Stockholder, or any underwriter.
This prospectus does not constitute an offer to sell, or a solicitation of any
offer to buy, common stock in any jurisdiction to any person to whom, it is
unlawful to make such an offer or solicitation in such jurisdiction. Neither
the delivery of this prospectus nor any sale made under this prospectus shall,
under any circumstances, create any implication that the information contained
in this prospectus is correct as of any time after the date of the prospectus
or that there has been no change in the affairs of OSI Systems, Inc. after the
date of this prospectus.
-----------------
- --------------------------------------
- --------------------------------------
- --------------------------------------
- --------------------------------------
1,781,793 SHARES
OSI SYSTEMS, INC.
COMMON STOCK
-----------------
PROSPECTUS
-----------------
November , 2001
- --------------------------------------
- --------------------------------------
PART II
ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION
The following table sets forth an itemized estimate of fees and expenses
payable by the registrant in connection with the offering described in this
registration statement:
SEC registration fee............. $ 5,628
NASDAQ additional listing fee.... $15,818
Counsel fees and expenses........ $25,000
Accounting fees and expenses..... $ 7,500
Blue Sky fees and expenses....... $ --
Transfer agent and registrar fees $ 2,000
Miscellaneous.................... $ 2,000
Total......................... $57,946
All of the above expenses will be paid by the registrant.
ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS
Section 317 of the California General Corporations Law authorizes a court to
award, or a corporation's board of directors to grant, indemnity to directors
and officers who are parties or are threatened to be made parties to any
proceeding (with certain exceptions) by reason of the fact that the person is
or was an agent of the corporation, against expenses, judgments, fines,
settlements and other amounts actually and reasonably incurred in connection
with the proceeding if that person acted in good faith and in a manner the
person reasonably believed to be in the best interests of the corporation.
Section 204 of the law provides that this limitation on liability has no
effect on a director's liability (a) for acts or omissions that involve
intentional misconduct or a knowing and culpable violation of law, (b) for acts
or omissions that a director believes to be contrary to the best interests of
the corporation or its shareholders or that involve the absence of good faith
on the part of the director, (c) for any transaction from which a director
derived an improper personal benefit, (d) for acts or omissions that show a
reckless disregard for the director's duty to the corporation or its
shareholders in circumstances in which the director was aware, or should have
been aware, in the ordinary course of performing a director's duties, of a risk
of a serious injury to the corporation or its shareholders, (e) for acts or
omissions that constitute an unexcused pattern of inattention that amounts to
an abdication of the director's duty to the corporation or its shareholders,
(f) under Section 310 of the law (concerning contracts or transactions between
the corporation and a director), or (g) under Section 316 of the law
(directors' liability for improper dividends, loans and guarantees). Section
317 does not extend to acts or omissions of a director in his capacity as an
officer. Further, Section 317 has no effect on claims arising under federal or
state securities laws and does not affect the availability of injunctions and
other equitable remedies available to our shareholders for any violation of a
director's fiduciary duty to us or our shareholders. Although the validity and
scope of the legislation underlying Section 317 have not yet been interpreted
to a significant extent by the California courts, Section 317 may relieve
directors of monetary liability to us for grossly negligent conduct, including
conduct in situations involving attempted takeovers of our company.
In accordance with Section 317, our articles of incorporation eliminate the
liability of each of our directors for monetary damages to the fullest extent
permissible under California law. Our articles further authorize us to provide
indemnification to our agents (including our officers and directors), subject
to the limitations set forth above. We have entered into indemnification
agreements with our officers and directors consistent with the foregoing
provisions.
II-1
Additionally, we maintain insurance policies which insure our officers and
directors against certain liabilities. The foregoing summaries are necessarily
subject to the complete text of the statute, our articles, our bylaws and the
agreements referred to above and are qualified in their entirety by reference
thereto.
ITEM 16. EXHIBITS
Exhibit No. Description
- ----------- -----------
5 Opinion of Richman, Mann, Chizever, Phillips & Duboff
23.1 Consent of Richman, Mann, Chizever, Phillips & Duboff. (included in Exhibit 5)
23.2 Consent of Deloitte & Touche LLP
ITEM 17. UNDERTAKINGS
The undersigned registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a
post-effective amendment to this registration statement to include any
material information with respect to the plan of distribution not
previously disclosed in the registration statement or any material
change to such information in the registration statement.
(2) That, for the purpose of determining any liability under the Securities
Act of 1933, each such post-effective amendment shall be deemed to be a
new registration statement relating to the securities offered therein,
and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any
of the securities being registered which remain unsold at the
termination of the offering.
(4) That, for purposes of determining any liability under the Securities Act
of 1933, each filing of the registrant's annual report pursuant to
Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and,
where applicable, each filing of an employee benefit plan's annual
report pursuant to Section 15(d) of the Securities Exchange Act of 1934)
that is incorporated by reference in the registration statement shall be
deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.
(5) Insofar as indemnification for liabilities arising under the Securities
Act of 1933 may be permitted to directors, officers and controlling
persons of the registrant pursuant to the provisions described in Item
15, or otherwise, the registrant has been advised that in the opinion of
the Securities and Exchange Commission such indemnification is against
public policy as expressed in the Securities Act and is, therefore,
unenforceable. In the event that a claim for indemnification against
such liabilities (other than the payment by the registrant of expenses
incurred or paid by a director, officer or controlling person of the
registrant in the successful defense of any action, suit or proceeding)
is asserted by such director, officer or controlling person in
connection with the securities being registered, the registrant will,
unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as
expressed in the Securities Act and will be governed by the final
adjudication of such issue.
II-2
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant
certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-3 and has duly caused this amended
Registration Statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of Hawthorne, State of California, on this 16th
day of November, 2001.
OSI Systems, Inc.
/s/ DEEPAK CHOPRA
By: _________________________________
Deepak Chopra
President and Chief Executive
Officer
Pursuant to the requirements of the Securities Act of 1933, this
registration statement has been signed below by the following persons in the
capacities and on the dates indicated.
Signature Title Date
--------- ----- ----
/s/ DEEPAK CHOPRA Chairman of the Board, President November 16, 2001
- ------------------------ and Chief Executive Officer
Deepak Chopra (Principal Executive Officer)
/s/ AJAY MEHRA Vice President, Chief Financial November 16, 2001
- ------------------------ Officer (Principal Financial and
Ajay Mehra Accounting Officer), Secretary
and Director
/s/ STEVEN C. GOOD Director November 16, 2001
- ------------------------
Steven C. Good
/s/ MEYER LUSKIN Director November 16, 2001
- ------------------------
Meyer Luskin
/s/ MADAN G. SYAL Director November 16, 2001
- ------------------------
Madan G. Syal
/s/ CHAND R. VISWANATHAN Director November 16, 2001
- ------------------------
Chand R. Viswanathan
II-3
EXHIBIT 5
November 16, 2001
OSI Systems, Inc.
12525 Chadron Avenue
Hawthorne, CA 90250
Re: Common Stock of OSI Systems, Inc.
Gentlemen:
We have acted as counsel to OSI Systems, Inc., a California corporation (the
"Company"), in connection with the preparation and filing with the United
States Securities and Exchange Commission under the Securities Act of 1933, as
amended, of the Company's registration statement on Form S-3 (the "Registration
Statement"), relating to the registration for resale of 1,781,793 shares of the
Company's Common Stock, no par value per share (the "Common Shares"), which
were issued in connection with the transactions contemplated by the Stock
Purchase Agreement, dated November 5, 2001 (the "Agreement"), between the
Company and certain investors.
In arriving at the opinions expressed below, we have reviewed the Agreement
and the Registration Statement and the Exhibits thereto. In addition, we have
reviewed the originals or copies certified or otherwise identified to our
satisfaction of all such corporate records of the Company and such other
instruments and other certificates of public officials, officers and
representatives of the Company and such other persons, and we have made such
investigations of law, as we have deemed appropriate as a basis for the
opinions expressed below. In rendering the opinions expressed below, we have
assumed that the signatures on all documents that we have reviewed are genuine
and that the Common Shares will conform in all material respects to the
description thereof set forth in the Registration Statement.
Based on the foregoing, we are of the opinion that the Common Shares to be
issued pursuant to the Agreement have been duly authorized by all necessary
corporate action of the Company and, when issued in accordance with such
authorization and delivered will be validly issued, fully paid, and
nonassessable.
The foregoing opinions are limited to the federal law of the United States
of America and the General Corporation Law of the State of California.
We hereby consent to the filing of this opinion as Exhibit 5 to the
Registration Statement and to the use of our name under the caption "Legal
Matters" in the Registration Statement and in the Prospectus included therein.
Very truly yours,
/s/ RICHMAN, MANN, CHIZEVER, PHILLIPS &
DUBOFF
Exhibit 23.2
INDEPENDENT AUDITORS' CONSENT
We consent to the incorporation by reference in this Registration Statement
of OSI Systems, Inc. on Form S-3 of our report dated September 17, 2001,
appearing in the Annual Report on Form 10-K of OSI Systems, Inc. for the year
ended June 30, 2001.
/s/ DELOITTE & TOUCHE LLP
Los Angeles, California
November 14, 2001
1